| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | TNG462 Pancreatic cancer — monotherapy (intended registrational population) | Phase 1/2 | — | Small Molecules | Oncology | ||
Phase 1/2 data readout example | TNG462 Pancreatic cancer — monotherapy (intended registrational population) | Phase 1/2 | — | Small Molecules | Oncology | ||
Phase 1/2 data readout example | TNG462 Pancreatic cancer — monotherapy (intended registrational population) | Phase 1/2 | — | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Tango Therapeutics, Inc.$28.39
+0.09 (+0.32%)
B 77Pipeline Score Undervalued Biotech · Commercial
Market Cap
2.93 B
EPS
-0.82
P/E Ratio
-
Value Trade
28.44 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
33.53 M
Operating CF
-44.36 M
Total Assets
435.79 M
Total Liabilities
44.29 M
Equity
391.51 M
D/E Ratio
12,345
-12.38 %
Week
-27.71 %
1 Month
65.49 %
3 Month
134.8 %
6 Month
80.71 %
5 Year
104.86 %
All Time
Cash Data
Cash Position
379.84 M
Monthly Burn
14.79 M
Runway
24.5 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
5.39 M
52 Week Range
1.91 - 28.41
% held by Insiders
26.72 %
% held by Institutions
88.57 %
Enterprise Value
2.58 B
Total Shares
144.24 M
Short %
25.97 %
Float Shares
128.95 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B77
Pipeline Score $25.9B
Pipeline ValueUndervalued
Valuation Signal54
Drugs Scored8.8x
rNPV / MCap Top 97%
Small Cap (rank 28 of 905)
Percentile RankTango Therapeutics, Inc. holds a solid B-grade pipeline (77/100), with $39.8B risk-adjusted pipeline value, led by Perindopril-indapamide in Diabetes Mellitus, Type 2 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perindopril-indapamide Small molecule | Diabetes Mellitus, Type 2 | Phase 3 | NCT00145925 | 58% | $15.0B | COMPLETED | 11,140 | - | - | Mar 1, 2008 | - | Apr 11, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TNG462 | MTAP-de pancreatic cancer,lung cancer | Phase 1/2 | 2025-08-06 | |||
TNG462 | MTAP-de pancreatic cancer,lung cancer | Phase 1/2 | 2025-08-06 | |||
TNG462 | MTAP-de pancreatic cancer,lung cancer | Phase 1/2 | 2025-08-06 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TNGX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
TNGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TNGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TNGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TNGX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
TNGX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TNGXTango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics has appointed Robert Azelby to its Board of Directors, bringing over 30 years of biopharmaceutical experience. His expertise in oncology and corporate strategy is expected to aid Tango in advancing its investigational drug, vopimetostat, towards late-stage development for pancreatic cancer. This appointment reflects Tango's commitment to enhancing its leadership as it transitions from research to commercialization.
Read more →TNGXTango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
Tango Therapeutics has announced the pricing of an underwritten public offering of approximately $600 million. The offering includes 18,166,667 shares of common stock priced at $30.00 each, along with pre-funded warrants. The expected closing date is June 11, 2026, pending customary conditions. The company aims to use the proceeds to advance its cancer therapeutics.
Read more →TNGXTango Therapeutics Announces Proposed $500 Million Public Offering
Tango Therapeutics has announced a proposed public offering of $500 million in common stock to fund its precision cancer medicine initiatives. The offering is underwritten by J.P. Morgan and other financial institutions, with an additional option for underwriters to purchase more shares. However, the completion of the offering is contingent on market conditions.
Read more →TNGXTango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
Tango Therapeutics reported promising results from its ongoing Phase 1/2 trial combining vopimetostat and daraxonrasib for treating metastatic pancreatic ductal adenocarcinoma (PDAC). The combination achieved a 92% objective response rate and a 90% six-month progression-free survival rate. The company plans to advance this combination into Phase 3 trials, aiming to provide a chemotherapy-free treatment option for patients with MTAP-deleted pancreatic cancer.
Read more →TNGXTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics, Inc. has announced the granting of a non-qualified stock option and restricted stock units to a new employee as part of its 2023 Inducement Plan. This plan is designed to attract new talent under Nasdaq Listing Rule 5635(c)(4). The stock options, priced at $23.10 per share, will vest over a period, while the RSUs will vest in equal annual installments. These actions reflect Tango's aims to enhance employee retention and support its growth in the biotechnology field.
Read more →TNGXTango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of
Tango Therapeutics has reported its financial results for the first quarter of 2026, highlighting key business developments and a strong cash position of $380 million. The company remains focused on advancing its vopimetostat candidate in pivotal studies for pancreatic cancer, with upcoming initial data expected in 2026. Recent leadership changes aim to support the late-stage clinical development of their drug candidates. However, the company reported an increased net loss compared to the previous year, attributed to a decline in collaboration revenue and expenses related to its research and development activities.
Read more →TNGXTango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat - Matthew Gall appointed Chief Financial Officer - - Additional key appointments add expertise in clinical operati
Tango Therapeutics has announced several key leadership appointments to accelerate the late-stage development of vopimetostat, a PRMT5 inhibitor targeting pancreatic cancer. Matthew Gall joins as Chief Financial Officer, with Yen-Ching Chua and Janice Kapty, PhD taking on roles in clinical operations and corporate strategy, respectively. The company's CEO highlighted the importance of these changes in driving growth and preparing for potential regulatory approval, along with a commitment to present key clinical data later this year. The leadership additions aim to enhance Tango's strategic and operational capacity as it moves towards commercialization.
Read more →TNGXTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2026
Tango Therapeutics announced the grant of stock options and restricted stock units to a new employee as part of its 2023 Inducement Plan. The options, totaling 367,500 shares, have an exercise price of $11.94 per share, matching the stock's closing price on the grant date. The RSUs will vest over three years, contingent on continued employment.
Read more →TNGXTango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Tango Therapeutics reported its financial results for Q4 and full year 2025, highlighting a strong cash position of $343 million and ongoing robust enrollment in clinical trials for its lead product, vopimetostat. The company is set to initiate a pivotal study in 2L pancreatic cancer in 2026 and has entered a supply agreement with Erasca for further exploration of vopimetostat's potential. Despite a net loss increase, the company remains optimistic about its pipeline and strategic collaborations.
Read more →TNGXTango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
Tango Therapeutics, Inc. (NASDAQ: TNGX) will announce its fourth quarter 2025 financial results on March 5, 2026, prior to the U.S. market opening. The company will not hold a conference call but will participate in three upcoming investor conferences. These events will be available via live webcast and archived for 90 days.
Read more →TNGXTango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Tango Therapeutics will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, with CEO Malte Peters scheduled for a fireside chat. The event is set for February 12, 2026, and will be available via a live webcast. The company focuses on precision medicine and synthetic lethality in cancer treatment.
Read more →TNGXTango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
Tango Therapeutics announced the retirement of CEO Dr. Barbara Weber, who will become Executive Chair. Dr. Malte Peters, a board member since 2018, has been appointed as the new CEO. Dr. Weber praised Peters' leadership and expertise, particularly in late-stage clinical development. The company aims to continue its growth and advance its clinical pipeline under Peters' leadership.
Read more →TNGXTango Therapeutics Appoints Sung Lee to Board of Directors
Tango Therapeutics has appointed Sung Lee to its Board of Directors, enhancing its leadership team. Lee, with over 20 years of experience in finance within the biopharmaceutical sector, is expected to contribute significantly to the company's strategic goals. His background includes roles at Cytokinetics and Gilead Sciences, which will support Tango's late-stage clinical development efforts.
Read more →TNGXTango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced its participation in the upcoming 44th Annual J.P. Morgan Healthcare Conference where CEO Dr. Barbara Weber will present. The event is scheduled for January 14, 2026, at 9:45 am PST/12:45 pm EST. The presentation will be accessible via a live webcast and will be archived for 90 days on the company’s website, which enhances investor engagement opportunities. Tango Therapeutics focuses on developing precision medicine for cancer treatment leveraging synthetic lethality.
Read more →TNGXTango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Tango Therapeutics, Inc. announced that Dr. Adam Crystal will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3. The event will be accessible via a live webcast, which will also be archived for 90 days. This participation highlights Tango's focus on advancing cancer therapies.
Read more →TNGXTango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
Tango Therapeutics, Inc. (NASDAQ: TNGX) has announced its participation in the 2025 Jefferies Global Healthcare Conference, where CEO Barbara Weber will engage in a fireside chat. This event is scheduled for November 19, 2025. The live webcast will be accessible via the company's website, and a replay will be available for 90 days. Tango Therapeutics specializes in developing novel drug targets and therapies utilizing principles of precision medicine aimed at cancer treatment.
Read more →TNGXTango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights – Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS
Tango Therapeutics reported its third quarter 2025 financial results, highlighting positive clinical data for its candidate vopimetostat in treating MTAP-deleted pancreatic cancer, which demonstrated a median progression-free survival of 7.2 months. The company also reported robust enrollment in ongoing combination studies and secured $225 million in financing, extending its operational runway into 2028. However, it continues to face net losses and has not generated license revenue in the recent quarter. Looking forward, Tango anticipates important clinical updates in 2026.
Read more →TNGXTango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Tango Therapeutics, Inc. has announced that it will release its financial results for the third quarter of 2025 on November 4, 2025, at 9:00 AM ET. The results will be provided before the U.S. financial markets open. Notably, the company has chosen not to hold a conference call following the report. Tango Therapeutics is focused on developing therapies for cancer by utilizing the concept of synthetic lethality.
Read more →TNGXDisclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango's future financial and operat
Tango Therapeutics has provided a clinical update on Vopimetostat (TNG462), an oral PRMT5 inhibitor, which is being evaluated for multiple cancers. The company presents optimistic potential for the drug, citing ongoing clinical trials that indicate durable tumor control and an expected better safety profile compared to competitors. However, the update includes cautionary notes regarding the company's limited operating history, previous operating losses, and uncertainties surrounding future clinical trial results, suggesting that risks remain prevalent in Tango’s pathway to profitability.
Read more →TNGXTango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
Tango Therapeutics has reported promising data from its Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers, highlighting a 49% objective response rate (ORR) and a median progression-free survival (mPFS) of 9.1 months in a histology-agnostic cohort. In patients with 2L MTAP-deleted pancreatic cancer, vopimetostat demonstrated a 25% ORR with a mPFS of 7.2 months, exceeding historical controls. The company anticipates a pivotal study initiation in 2026, following positive FDA engagement on dosing. Vopimetostat is being evaluated in combination with RAS(ON) inhibitors, with ongoing data expected to emerge in 2026.
Read more →TNGXTango Therapeutics Announces $225 Million Financing
Tango Therapeutics has announced a significant financing round, pricing an underwritten offering of about 21 million shares at $8.66 each, aiming for gross proceeds of approximately $210 million. Additionally, a private investment in public equity (PIPE) will yield approximately $15 million. The offering closure is expected shortly, contingent upon customary conditions. The funds will support Tango's commitment to developing precision cancer medicines, leveraging novel targets in oncology.
Read more →TNGXTango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025
Tango Therapeutics, Inc. has announced its participation in the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where it will present three posters, including the first clinical data on its CoREST inhibitor TNG260. The drug is currently being tested alongside pembrolizumab in patients with STK11-mutant/RAS wild type lung cancer. The data presentation is scheduled for November 7, 2025, and aims to demonstrate the potential efficacy of TNG260 in enhancing anti-PD-1 therapy for specific types of lung cancer.
Read more →TNGXTango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
Tango Therapeutics, a clinical-stage biotechnology company, announced that its President and CEO, Dr. Barbara Weber, will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on September 3. The event will feature a live webcast, ensuring broad access for interested parties. Following the event, a replay will be available for 90 days on the company's website. This participation highlights Tango's role in advancing precision medicine in cancer treatment.
Read more →TNGXTango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights – First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – –
Tango Therapeutics reported its second quarter 2025 financial results, highlighting advancements in their clinical trials for TNG462, a promising combination therapy targeting MTAP-del pancreatic and lung cancers. Notably, the first patient has been dosed in the combination trial with RAS(ON) inhibitors. The company also discussed ongoing trials for TNG456 and TNG260, while acknowledging an increase in net losses and a decline in collaboration revenue compared to the previous year. Despite financial challenges, Tango remains focused on developing innovative cancer treatment solutions.
Read more →TNGXTango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
Tango Therapeutics, a clinical-stage biotechnology company, announced that it will report its second quarter 2025 financial results on August 5, 2025. The results will be published before the U.S. markets open, but the company has stated it will not hold a conference call to discuss the findings. Tango Therapeutics focuses on precision medicine for cancer treatment, utilizing synthetic lethality to devise novel therapies.
Read more →TNGXTango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
Tango Therapeutics has announced the dosing of its first patient in a Phase 1/2 trial for TNG462 in combination with daraxonrasib or zoldonrasib, targeting patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer. This combination therapy aims to leverage the strong preclinical data indicating potential transformative effects in treating these cancers. The trial will evaluate various parameters including safety, pharmacokinetics, and antitumor activity. The upcoming monotherapy data for TNG462 is expected later in 2025, which could inform future registrational trials for pancreatic cancer.
Read more →TNGXTango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Tango Therapeutics, Inc. will have its CEO, Barbara Weber, participate in a fireside chat at the upcoming 46th Annual Goldman Sachs Global Healthcare Conference on June 10. The event will feature a live webcast available on the company's website, with an archived replay accessible for 90 days post-event. Tango Therapeutics, a clinical-stage biotechnology firm, is dedicated to developing precision cancer therapies through novel drug targets.
Read more →TNGXTango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
Tango Therapeutics has announced the dosing of the first patient in its TNG456 Phase 1/2 trial targeting MTAP-deleted solid tumors, particularly glioblastoma. TNG456 is a next-generation PRMT5 inhibitor designed for brain penetration. The clinical trial aims to assess safety and efficacy as a monotherapy and in combination with abemaciclib. With 45% of glioblastoma cases being MTAP-deleted, the company highlights the potential impact of TNG456 for patients with limited treatment options.
Read more →TNGXTango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights – Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial o
Tango Therapeutics reported its financial results for Q1 2025, indicating a net loss of $39.9 million, despite maintaining a robust cash position of $217 million. The company is on track to release a major data update on its TNG462 monotherapy later this year and plans to initiate a registrational study in pancreatic cancer. Additionally, Tango is advancing clinical trials for combinations of TNG462 with Revolution Medicines' inhibitors. However, the decline in collaboration revenue and increased spending on certain development programs pose financial challenges.
Read more →TNGXTango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Tango Therapeutics, Inc. (NASDAQ: TNGX) has announced it will report its financial results for the first quarter of 2025 on May 12, 2025, prior to the opening of U.S. markets. Notably, the company has chosen not to hold a conference call following this report. Tango Therapeutics is focused on developing novel therapies for cancer treatment based on the principle of synthetic lethality. Investors and stakeholders are encouraged to stay informed through the company's communications.
Read more →TNGXTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
Tango Therapeutics has announced five accepted abstracts for poster presentations at the AACR Annual Meeting 2025 in Chicago. The data focuses on preclinical analyses of their PRMT5 inhibitors, suggesting potential use as standalone treatments and in combination with other therapies for MTAP-deleted cancers. Presentations will cover topics including CNS drug penetration and genetic disruptions in cancer treatments. Despite the promising data, there are uncertainties regarding clinical trial execution and product viability.
Read more →TNGXTango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights – TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investi
Tango Therapeutics reported its financial results for Q4 and the full year of 2024, announcing positive developments, including the Orphan Drug Designation for TNG462 for pancreatic cancer and FDA clearance for the IND application of TNG456. The company will begin enrolling patients in clinical trials for both TNG456 and TNG462 in 2025. Despite these advancements, Tango reported a net loss of $37.7 million for Q4 2024, reflecting an increase from the previous year. The company's strong cash position is projected to support operations into Q3 2026.
Read more →TNGXTango Therapeutics to Present at Three Upcoming Investment Bank Conferences
Tango Therapeutics, a clinical-stage biotechnology company, has announced its participation in three upcoming investment bank conferences. The events include the B Riley Precision Oncology & Radiopharma Conference, the Leerink Global Healthcare Conference, and the Barclays 27th Annual Global Healthcare Conference, scheduled for late February and March 2025. The company plans to discuss its innovative approaches to cancer treatment, particularly focusing on synthetic lethality. These engagements aim to strengthen investor relations and showcase the company's ongoing commitment to developing novel cancer therapies.
Read more →TNGXTango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
Tango Therapeutics, a clinical-stage biotechnology firm, will be featured in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on February 5, 2025. The session will be led by CEO Barbara Weber, M.D., and will focus on the company's innovative approach to precision cancer treatments. Interested parties can access a live webcast of the chat and find further information on Tango's website. This event highlights the company's efforts in advancing cancer therapies through novel drug targets.
Read more →TNGXThe next wave of targeted therapies in oncology Corporate Overview January 2025 | 1 Disclaimer and Safe Harbor Statement Certain statements in this presentation may be considered forward-looking statements. Forward-looki
Tango has provided an overview of its corporate strategy and future goals in oncology, focusing on the potential of its product pipeline, particularly its PRMT5 inhibitors. The company anticipates significant opportunities in treating various cancers with its drug candidates, including TNG260 and TNG462. However, Tango faces notable challenges, including a lack of revenue, potential delays in clinical trial initiation, and the risks associated with unproven development strategies. The company emphasizes the uncertainties involved in drug development and its reliance on external partners for conducting trials.
Read more →TNGXTango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights – Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into
Tango Therapeutics has reported strong financial results for Q3 2024, with significant progress on its TNG462 clinical trial showing positive activity across several cancer types. The company is advancing TNG462 into full development and collaborating with Revolution Medicines for additional combination studies. Despite a robust cash position of $293 million, the company reported an increased net loss compared to the previous year. Additionally, TNG908 enrollment has been stopped to prioritize resources towards TNG462.
Read more →TNGXTango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights – Dose expansion ongoing in TNG908 and TNG462 phase 1/2 clinical trials; comprehensive clinical data update for the
Tango Therapeutics reported its financial results for the second quarter of 2024, highlighting ongoing dose expansion in its TNG908 and TNG462 clinical trials. The company maintains a robust cash position of $322 million, projected to sustain operations through 2027. Alongside continuous patient enrollment for TNG260, Tango aims for a comprehensive update on its PRMT5 program in the second half of the year. However, the company faced a net loss of $25.6 million for the quarter, alongside a decrease in collaboration revenue.
Read more →TNGXTango Therapeutics Announces Discontinuation of TNG348 Program The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts Cash runway extended into
Tango Therapeutics has announced the discontinuation of its TNG348 program, a USP1 inhibitor, following reports of liver toxicity in patients during a phase 1/2 clinical trial. The decision underscores the company's commitment to patient safety. Despite this setback, Tango has extended its cash runway to 2027 and plans to redirect resources towards its existing clinical programs, particularly PRMT5, while promising upcoming updates on other pipeline candidates. This development raises concerns about the implications for investor sentiment and the company's future prospects in precision oncology.
Read more →TNGXTango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights – Dose expansion initiated in TNG908 phase 1/2 clinical trial – – Dose expansion expected to initiate
Tango Therapeutics has reported its financial results for the first quarter of 2024, highlighting the initiation of dose expansions in the TNG908 and TNG462 clinical trials. The company holds a strong cash position of $344 million, enabling it to fund operations into late 2026. Upcoming clinical data from its PRMT5 program is anticipated in the second half of 2024, while ongoing trials for TNG260 and TNG348 continue to show favorable safety profiles. However, the net loss for the quarter increased compared to the previous year, signaling financial challenges ahead.
Read more →TNGXTango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights – Dose escalation ongoing in four clinical-stage precision oncology programs; TNG908 phase 1/2 clinic
Tango Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting ongoing dose escalation in four clinical-stage precision oncology programs. The company received FDA Orphan Drug Designation for TNG462 aimed at treating soft tissue sarcomas and commenced patient enrollment in the TNG348 phase 1/2 trial. Despite a strong cash position of $337 million, the net loss for the quarter increased slightly compared to the previous year. Tango remains on track to provide clinical data for TNG908 in 2024, indicating continued advancement of its oncology pipeline.
Read more →TNGXTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
Tango Therapeutics, Inc. has announced that it will showcase new preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego. This includes one abstract selected for an oral presentation and seven additional abstracts for poster presentations. Among the highlighted research is the small molecule CoREST inhibitor TNG260 and its effectiveness in treating STK11-mutant non-small cell lung cancer in combination with anti-PD1 immunotherapy. The meeting is scheduled for April 5-10, 2024.
Read more →TNGXTango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
Tango Therapeutics, a clinical-stage biotechnology company, announced that its CEO, Dr. Barbara Weber, will present at the Guggenheim Healthcare Talks during the 6th Annual Biotechnology Conference on February 7, 2024. The presentation will focus on the company’s advancements in precision cancer medicine. A live webcast of the event will be available, with a replay accessible for 30 days post-presentation. Tango Therapeutics emphasizes its commitment to discovering novel therapies targeted at cancer treatment through innovative approaches like synthetic lethality.
Read more →TNGXTango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
Tango Therapeutics has announced the dosing of the first patient in their Phase 1/2 trial assessing TNG348 for BRCA1/2-mutant and other HRD+ cancers. This milestone marks a significant step forward in their clinical-stage pipeline, which aims to develop precision cancer therapies. TNG348, a selective inhibitor of USP1, has previously demonstrated promising anti-tumor activity in preclinical models. With the FDA granting Fast Track designation for TNG348, the company is optimistic about its potential in treating advanced cancers linked to DNA repair defects.
Read more →TNGXTango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
Tango Therapeutics is set to present preclinical data on its PRMT5 inhibitors, TNG908 and TNG462, at the SNO 28th Annual Meeting. These inhibitors are being developed for treating MTAP-deleted cancers, including glioblastoma and malignant peripheral nerve sheath tumors. The data presented indicates significant antitumor activity in preclinical models, highlighting the potential of these drugs as new therapeutic approaches. Ongoing phase 1/2 clinical trials continue to assess their efficacy and safety.
Read more →TNGXTango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights – Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical
Tango Therapeutics reported its financial results for the third quarter of 2023, highlighting ongoing dose escalations in several clinical trials for its lead PRMT5 inhibitors, TNG908 and TNG462. The company received FDA Fast Track designation for TNG348, a novel USP1 inhibitor aimed at treating BRCA1/2-mutant cancers. With a robust cash position of $360 million, Tango anticipates funding its clinical programs into 2026. Despite a net loss of $22.3 million reported for the quarter, the company's strategic advancements in precision oncology are notable.
Read more →TNGXTango Therapeutics to Present at the Jefferies London Healthcare Conference
Tango Therapeutics, a clinical-stage biotechnology company, has announced that its CEO, Dr. Barbara Weber, will present at the Jefferies London Healthcare Conference on November 14, 2023. The presentation will be available via a live webcast, which will also be archived on the company's website for 90 days. Tango Therapeutics is recognized for its commitment to discovering novel drug targets in the realm of precision cancer medicines, utilizing approaches like synthetic lethality. This upcoming presentation highlights the company's efforts toward advancing cancer treatment.
Read more →TNGXTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Tango Therapeutics announced that five of its abstracts have been selected for poster presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference is scheduled to take place in Boston from October 11-15, 2023. The focus will be on their innovative research in precision oncology, particularly around the drug candidates focusing on molecular targets and cancer therapies. The company is committed to advancing its research pipeline targeting critical cancer mechanisms.
Read more →TNGXTango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers
Tango Therapeutics announced that the FDA has cleared its Investigational New Drug application for TNG348, a novel USP1 inhibitor targeting BRCA1/2-mutant and other HRD+ cancers. The phase 1/2 clinical trial is set to begin in the first half of 2024, evaluating TNG348 alone and in combination with olaparib. Newly released preclinical data suggest that TNG348 may provide effective treatment options for patients who have developed resistance to PARP inhibitors. This development marks a significant step forward for the company's precision cancer medicine efforts.
Read more →TNGXTango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Tango Therapeutics, a clinical-stage biotechnology company, announced that its CEO, Barbara Weber, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11, 2023. This participation is part of the company's efforts to promote its innovative approach to cancer therapies, particularly focusing on precision medicine. A live webcast of the presentation will be available, and a recording will be archived for 90 days. This event is an opportunity for the company to engage with potential investors and stakeholders.
Read more →TNGXTango Therapeutics Announces Updates to Its Board of Directors
Tango Therapeutics, a clinical-stage biotechnology company, has announced updates to its Board of Directors, with John Ketchum joining as a new member and Aaron Davis stepping down. Ketchum brings over 30 years of biopharmaceutical experience, particularly in oncology, which is expected to aid the company as it advances its pipeline of precision cancer therapies. The company is currently focused on its clinical trials, with substantial data anticipated next year for its lead candidate, TNG908. CEO Barbara Weber expressed gratitude towards Davis for his significant contributions during his tenure.
Read more →TNGXTango Therapeutics Announces $80 million Private Placement Financing
Tango Therapeutics, a clinical-stage biotechnology company, announced an $80 million private placement financing led by Nextech and other investors. The financing will support ongoing development of their PRMT5 inhibitors and various clinical trials, including TNG908 and TNG260. The anticipated proceeds will further strengthen operations through 2026 and demonstrate investor confidence in Tango's precision oncology platform. However, the financing's completion is subject to closing conditions and highlights the company's reliance on upcoming clinical data.
Read more →TNGXTango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights – First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-del
Tango Therapeutics reported notable advancements in their clinical pipeline, highlighted by the dosing of the first patients in three phase 1/2 trials, focusing on next-generation PRMT5 inhibitors for MTAP-deleted tumors and a CoREST complex inhibitor for STK11-mutant cancers. They showcased improvements in financial performance, with collaboration revenue increasing significantly compared to last year, while holding substantial cash reserves to support operations into 2026. However, the company also noted a net loss which has risen relative to the same period last year, alongside a change in leadership, as Alan Huang steps down and Jannik Andersen assumes the role of Chief Scientific Officer.
Read more →TNGXTango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers
Tango Therapeutics has initiated a Phase 1/2 clinical trial for TNG260, evaluating its effectiveness combined with pembrolizumab in patients with STK11-mutant cancers. This trial aims to address the challenge of immune evasion associated with these mutations. It marks a significant step in the use of genetic biomarkers to select patients for specific therapies. Additionally, the FDA has granted Fast Track designation for TNG260, which may expedite its development timeline.
Read more →TNGXTango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics announced that the first patient has been dosed in a Phase 1/2 trial of TNG462, targeting MTAP-deleted solid tumors. This trial is significant as MTAP deletions affect 10-15% of solid tumors, and no FDA-approved treatments currently exist for these patients. TNG462, a MTA-cooperative PRMT5 inhibitor, has received Fast Track designation, reflecting its potential in treating this specific cancer subset. The company is also advancing another compound, TNG908, which is being evaluated in an ongoing study.
Read more →TNGXTango Therapeutics to Participate in Upcoming Investor Conferences
Tango Therapeutics, Inc. (NASDAQ: TNGX) has announced its participation in two upcoming investor conferences: the Jefferies Healthcare Conference on June 9, 2023, in New York, and the Goldman Sachs 44th Annual Global Healthcare Conference on June 14, 2023, in Dana Point, CA. The company plans to provide live webcasts of the presentations, which will also be available for replay for 90 days after the events. Tango Therapeutics aims to develop precision cancer medicines using innovative approaches like synthetic lethality.
Read more →TNGXTango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights – Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-se
Tango Therapeutics reported its first quarter 2023 financial results and showcased notable advancements in its oncology pipeline. The ongoing TNG908 clinical trial confirmed proof-of-mechanism for its targeted therapy in MTAP-deleted cancers, while the FDA cleared the IND application for TNG260, a CoREST complex inhibitor. Additionally, TNG260 has received Fast Track designation for use with an anti-PD-1 antibody in treating advanced NSCLC. Tango remains well-funded, with a cash reserve of $334 million expected to support its initiatives through 2026.
Read more →TNGXTango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced highlights from presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida. Tango scientists p
Read more →TNGXTango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers
BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the U.S. Food and Drug Administration (FDA) h
Read more →TNGXTango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights – Fast Track Designation granted to TNG462, next-generation MTA-Cooperative PRMT5 inhibitor –
Tango Therapeutics announced its fourth-quarter and full-year financial results for 2022, highlighting advancements in its precision cancer medicine pipeline, including the FDA's Fast Track Designation for TNG462. The company reported increased net losses during the year despite new clinical developments involving TNG908 and ongoing trials focused on various cancer types. With robust cash reserves aimed to sustain operations until 2025, Tango is positioned to enhance its research and development efforts under the newly appointed President of Research and Development, Adam Crystal, M.D., Ph.D.
Read more →TNGXTango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, F
Read more →TNGXTango Therapeutics Announces Limited Exposure to Silicon Valley Bank
BOSTON, March 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported that it is aware of the current situation affecting Silic
Read more →TNGXTango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development
Tango Therapeutics has appointed Dr. Adam Crystal as the new President of Research and Development. Dr. Crystal joins the company at a pivotal moment, overseeing ongoing clinical trials and the advancement of new programs. With a robust background in precision oncology, he is expected to contribute significantly to the pipeline that aims to address unmet medical needs in cancer treatment. The leadership transition comes as the company actively expands its clinical endeavors.
Read more →TNGXTango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates
BOSTON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the U.S. Food and Drug Administration (FDA) ha
Read more →TNGXTango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights – Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency f
Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France TNG260 disclosed as a
Read more →TNGXTango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that three abstracts have been selected for presentation as poster
Read more →TNGXTango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting
CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that three abstracts have been selected for poster prese
Read more →TNGXTango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive
Read more →TNGXTango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights – Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of TNG908, an MTA-coop
Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of TNG908, an MTA-cooperative PRMT5 inhibitor Received Orphan Drug Designation in US for
Read more →TNGXTango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive
Read more →TNGXTango Therapeutics Added to Russell 2000 , 3000 and Microcap Indexes
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the company was added to the Russell 2000®, Russell
Read more →TNGXTango Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to par
Read more →TNGXTango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights – Phase 1/2 trial of TNG908, a synthetic lethal PRMT5 inhibitor, for the treatment of MTAP-deleted solid tumors open
Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights Phase 1/2 trial of TNG908, a synthetic lethal PRMT5 inhibitor, for the treatment of MTAP-deleted solid tumors open for enrollment Declared TNG462 as a development candidate - a nex
Read more →TNGXTango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022
CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to part
Read more →TNGXTango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights - TNG908 receives Fast Track designation, expects Phase 1/2 trial to start in 2Q 2022 - Pipeline programs pr
Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights - TNG908 receives Fast Track designation, expects Phase 1/2 trial to start in 2Q 2022 - Pipeline programs progressing throughout 2022 - - Strong cash position of $4
Read more →TNGXTango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that three abstracts have been selected for presentatio
Read more →TNGXTango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the presentation of an e-Poster at the 2022 European So
Read more →TNGXTango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates
- TNG908 IND cleared by FDA, Phase 1/2 trial expected to start in 1H 2022 - Additional pipeline programs progressing throughout 2022 CAMBRIDGE, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and
Read more →TNGXTango Therapeutics to Participate in the Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to par
Read more →TNGXTango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights Strong cash position of $504 million supports advancing discovery and clinical pipeline into second half of 2024 On track f
Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights Strong cash position of $504 million supports advancing discovery and clinical pipeline into second half of 2024 On track for IND filing in fourth quarter of 2021 for TNG908, an MT
Read more →TNGXTango Therapeutics Announces Appointment of Dr. Marc Rudoltz as Chief Medical Officer and Doug Barry as General Counsel
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced two recent senior management appointments: Marc Rudoltz,
Read more →TNGXMANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF TANGO Management s discussion and analysis of our financial condition and results of operations should be read together with Tango
MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF TANGO Management s discussion and analysis of our financial condition and results of operations should be read together with Tango s unaudited condensed consolidated financial statements a
Read more →TNGXTango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies
– Business combination transaction with BCTG Acquisition Corp., a special purpose acquisition company sponsored by Boxer Capital, completed today – – Combined company Tango Therapeutics, Inc. will be listed on the Nasdaq Capital Market under ticker symbol “TNGX” – – Total expec
Read more →TNGXTango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies - Leading institutional investors c
Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies Leading institutional investors commit $186 million through a common stock private investment
Read more →TNGXBCTG ACQUISITION CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 F- 1 Report of Independent Registered Public Accounting Firm To the Stockholders and t
Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 Report of Independent Registered Public To the Stockholders and the Board of Directors BCTG Acquisition Corp. Opinion on the Financial Statement We have audited the
Read more →Competitive Position
How TNGX ranks across every disease it competes inCompetitive Position is a premium feature
See how TNGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial